Mason cited this paper on 10 June in the Chat GPT thread and lo verily as usual he said "Show me an FTO inhibitor that is clinic ready (you can't), and then explain why it would be an effective competitor if preclinical evidence suggests FTO inhibition (inceased m6A levels) synergises with cardiotoxic drugs to KILL (emphasis added) HCM.""
So bisantrene's CP MOA must be stronger than the effect noted in the paper.
Speculative M&A Transaction Analysis, page-736
-
- There are more pages in this discussion • 5 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.57 |
Change
0.010(0.64%) |
Mkt cap ! $267.5M | |||
| Open | High | Low | Value | Volume |
| $1.58 | $1.64 | $1.55 | $134.0K | 84.34K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 6283 | $1.57 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.60 | 6559 | 2 |
View Market Depth
| Last trade - 16.10pm 15/08/2024 (20 minute delay) ? |
| RAC (ASX) Chart |